Slide 1: Q3:22 Financial Results
Exhibit 99.2 Q3:22 Financial Results November 2, 2022 1
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth
Slide 3: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements Additional forward-looking statements may be identified by words such as believe, expect, may, plan, potential, will, preliminary, and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to ris
Slide 4: Todd Newton, Interim CEO
Todd Newton Interim CEO 4 4
Slide 5: Four Key Priorities / Goals
Four Key Priorities / Goals* Grow Revenue Above Market Expand Operating Margins Execute on R&D Pipeline Exercise Financial Discipline Organization Focused on Capitalizing on These Opportunities 5 *Priorities / Goals are not intended to serve as company guidance. Actual results may differ
Slide 6: New Product & Market Progress
New Product & Market Progress Japan Offers superior handling Versatile placental-derived Secured reimbursement characteristics, providing particulate product available approval for EPIFIX surgeons with the capability for use in a wide range of First patients treated with EPIFIX to secure tissue in p
Slide 7: Q3:22 End Market Trends
Q3:22 End Market Trends July & August September Q3 Lower procedure volumes Demand rebounded, First year/year total sales & increased customer resulting in strong month growth quarter since vacation travel of sales Q2:21 7
Slide 8: Pete Carlson, CFO
Pete Carlson CFO 8 8
Slide 9: Business Units to be Reported as Segments
Business Units to be Reported as Segments Wound & Surgical • Continuing product portfolio • Related Sales & Marketing expense • Near-term product development initiatives Goal of providing visibility into our business units and Regenerative Medicine expense base as we seek to • Primarily focused on o
Slide 10: Segment Reporting
Segment Reporting* Wound & Surgical Regenerative Medicine Corporate & Other ($000s) Q3:22 Q3:21 % yoy Q3:22 Q3:21 % yoy Q3:22 Q3:21 % yoy - $76 nm Net Sales $66,873 $62,138 7.6% $816 $860 -5.1% Cost of Sales - 16 nm 11,159 8,924 25.0% 1,029 1,189 -13.5% Operating 4,273 4,230 1.0% 37,211 33,527 11.0%
Slide 11: Quarterly Net Sales
Quarterly Net Sales $80 $80 $70 $70 $60 $60 $50 $50 $40 $40 $30 $30 $20 $20 $10 $10 $0 $0 Total Wound & Surgical Q3:21 Q3:22 Q3:21 Q3:22 11 $ millions $ millions
Slide 12: Gross Profit & Margins
Gross Profit & Margins Gross Profit Gross Margin $55.5 83.9% 82.0% $52.9 Q3:21 Q3:22 Q3:21 Q3:22 12 $ millions
Slide 13: Q3 Operating Expenses
Q3 Operating Expenses Q3:21 vs. Q3:22 Operating Expenses 70 $62.6 60 $54.0 50 40 30 20 10 0 Q3:21 Q3:22 SG&A R&D Investigation, restatement and related Amortization of intangible assets 13 $ millions
Slide 14: Cash & Cash Equivalents
Cash & Cash Equivalents $87.1 $75.7 $73.2 $72.5 Q4:21 Q1:22 Q2:22 Q3:22 Data in $ millions 14
Slide 15: Q4:22 Outlook
Q4:22 Outlook Q4:22 Net Sales Outlook* 80 $73 to 76 Million 70 Q4:22 Net Sales expected in a range of $73 to 76 million 60 Reflects 8% to 15% growth over Q4:21 50 40 30 Full Year 2022 Net Sales expected in a range of 20 $266 to 269 million Reflects 11% to 12% growth over 2021 net sales of 10 continu
Slide 16: Todd Newton, Interim CEO
Todd Newton Interim CEO 16 16
Slide 17: KOA Update
KOA Update Recent FDA Interactions Type B RMAT meeting Submission of clinical protocol Filing of CMC amendments Study Status Resolving FDA protocol comments Readying for enrollment 17
Slide 18: Conclusion
Conclusion Q3:22 included several important achievements New segment reporting highlights: underlying revenue trends cost structure progress against our growth and profitability initiatives We have sufficient capital to execute our business plans 18
Slide 19: Q&A
Q&A 19 19